One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Truth and accountability
doi : 10.1016/S1470-2045(25)00486-3
Volume 26, Issue 9, September 2025, Page 1123
Refining risk stratification in meningiomas: beyond TERT promoter mutations
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer
Breaking the patient-reported outcome code in KRASG12C-mutated colorectal cancer: clinical interpretation of CodeBreaK 300
The importance of high-quality evidence supporting cancer drug approvals
Establishing the China–UK Cancer Prevention and Control Alliance
Clarifying the consensus on laryngeal preservation strategies – Authors' reply
Pitfalls in multinational sales data analysis – Authors' reply
Reflecting on the patient-reported outcomes from the EV-302 trial
The increasing costs of NCDs and mental health conditions in South America
US aid cuts affect vulnerable populations in the Democratic Republic of the Congo and Kenya
Broadening our view of power in clinician–patient relationships in oncology
Prevention and empowerment: cultural influences on prophylactic surgical decisions among BRCA mutation carriers in east Asia
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study
[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer
Oral lesion as the first sign of disseminated sarcomatoid carcinoma
